Ricolinostat is a selective HDAC6 inhibitor, which induces synergistic cell cytotoxicity in combination with proteasome inhibitors [15–17] and immunomodulatory agents [35, 36] in MM cell lines and animal models. The gene discussed is HDAC6; the disease is Miyoshi myopathy.